Zealand Pharma announces promising results from dapiglutide trial for obesity treatment
Zealand Pharma A/S (Nasdaq: ZEAL), a pioneer in peptide-based drug development, has shared topline results from its DREAM trial, evaluating the efficacy of low doses ... Read More
Lilly’s Zepbound marks remarkable weight loss milestone in SURMOUNT-4 study
In a significant development in the field of obesity treatment, Lilly's Zepbound (tirzepatide) has shown remarkable results in the SURMOUNT-4 study. Published in The Journal ... Read More
Roche to acquire Carmot Therapeutics to expand obesity treatment portfolio
Roche announced its definitive agreement to acquire Carmot Therapeutics, Inc., based in Berkeley, California, for an upfront purchase price of USD 2.7 billion, with additional ... Read More
Pfizer’s danuglipron shows promising results in Phase 2b obesity trial
Pfizer Inc. (NYSE: PFE) has announced encouraging topline data from its Phase 2b clinical trial (NCT04707313) investigating danuglipron, an oral Glucagon-like peptide-1 receptor agonist (GLP-1RA), ... Read More
Lilly bags Zepbound FDA approval for obesity treatment
The U.S. Food and Drug Administration has granted approval to Eli Lilly's Zepbound (tirzepatide) injection, making it the only obesity treatment that activates both GIP ... Read More
Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal
Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada's esteemed specialty pharmaceutical giant. This ... Read More
Novo Nordisk acquires Embark Biotech and enters R&D collaboration to advance obesity treatments
Novo Nordisk, a global leader in healthcare, has acquired Embark Biotech, including its lead metabolic program, in a deal that further strengthens its portfolio in ... Read More
Sugar Watchers raises Rs 3.6cr led by ah! Ventures, targets diabetic market
Sugar Watchers, a burgeoning health brand specializing in Low Glycemic Index (Low GI) staples, has successfully raised INR 3.6 crores in a recent funding round ... Read More
Lilly expands portfolio with $1.9bn acquisition of Versanis Bio
In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a ... Read More
Eli Lilly’s Tirzepatide triumphs in Phase 3 weight loss studies
Eli Lilly and Company has unveiled the results of two Phase 3 tirzepatide studies (SURMOUNT-3 and SURMOUNT-4) targeting adults with obesity or overweight with weight-related ... Read More